
PTD-DBM
Research Peptide | Lyophilized Powder | Batch Tested
For laboratory research use only. Not for human or animal consumption. Insulated shipping · Styrofoam box available.
Product Overview
PTD-DBM is a cell-penetrating research peptide designed to disrupt the interaction between CXXC5 and Dishevelled — a negative-feedback brake on the Wnt/β-catenin signaling pathway. Releasing this brake is studied as a strategy to reactivate regenerative signaling.
| Test | Result | Status |
|---|---|---|
| Purity | 98.6% | Passed ✓ |
Research Information
PTD-DBM is used to study activation of Wnt/β-catenin signaling in hair-follicle neogenesis and wound-healing models. It is frequently examined together with valproic acid (another Wnt activator) to study follicle regeneration in cosmetic and dermal research. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption.
PTD-DBM Research & Studies
What is PTD-DBM?
PTD-DBM is a synthetic cell-penetrating research peptide engineered to interfere with the protein-protein interaction between CXXC5 and Dishevelled. This interaction normally functions as a negative-feedback brake on the Wnt/β-catenin signaling cascade. Investigators use PTD-DBM in controlled laboratory systems to examine how releasing that brake influences regenerative pathway activity. The compound is supplied strictly for in-vitro and experimental research applications.
Mechanism of Action
PTD-DBM disrupts the binding interface between CXXC5 and Dishevelled, thereby relieving a key inhibitory constraint on Wnt/β-catenin signal transduction. Free Dishevelled can then more readily participate in the stabilization of β-catenin and subsequent nuclear signaling events. In experimental models this leads to measurable changes in pathway-responsive gene expression. The peptide’s cell-penetrating domain enables intracellular access without requiring additional delivery vehicles in most assay formats.
Primary Areas of Research
Laboratory studies of PTD-DBM center on hair-follicle neogenesis models, where Wnt/β-catenin activity is known to govern follicle development and cycling. Parallel work examines its effects in dermal wound-healing assays that track regenerative cellular responses. Researchers frequently co-apply PTD-DBM with valproic acid, another documented Wnt-pathway modulator, to explore combined pathway activation in these systems. All such investigations remain confined to in-vitro and non-clinical model platforms.
Key Research Findings
Published experimental work has shown that PTD-DBM elevates markers of Wnt/β-catenin pathway engagement in cultured dermal cells and tissue explants. In hair-follicle organoid and dermal-papilla models the peptide has been linked to increased expression of genes associated with regenerative programs. Co-treatment with valproic acid often amplifies these molecular readouts relative to either agent alone. Observed outcomes are restricted to laboratory model systems and do not extend beyond research contexts.
Research Handling & Considerations
PTD-DBM is intended solely for in-vitro and laboratory research use. Standard peptide storage and reconstitution practices should be followed to preserve structural integrity and activity. Investigators prepare working solutions under sterile conditions appropriate for cell-culture or biochemical assays. The material is not formulated or approved for any form of administration outside controlled experimental protocols.
Frequently Asked Questions
PTD-DBM is designed to block the binding of CXXC5 to Dishevelled, removing a negative-feedback restraint on Wnt/β-catenin signaling in research models.
Explore Other High-Purity Peptides

GHK-Cu

AHK-Cu

SNAP-8
